Uso del anifrolumab en el lupus eritematoso sistémico, lupus eritematoso cutáneo y otras dermatosis autoinmunes
D Martín-Torregrosa, M Mansilla-Polo… - Actas Dermo …, 2024 - Elsevier
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently
approved for the management of moderate-to-severe systemic lupus erythematosus (SLE) …
approved for the management of moderate-to-severe systemic lupus erythematosus (SLE) …
Anifrolumab for the Dermatologist
C Whiting, SA Azim, A Friedman - Journal of Drugs in Dermatology …, 2024 - jddonline.com
Anifrolumab for the Dermatologist - JDDonline - Journal of Drugs in Dermatology Close Search
JDDonline - Journal of Drugs in Dermatology Home Issues Current Issue eJDD Featured …
JDDonline - Journal of Drugs in Dermatology Home Issues Current Issue eJDD Featured …
This Month in JAAD Case Reports: April 2024: Anifrolumab for subacute cutaneous lupus
B Sloan - Journal of the American Academy of Dermatology, 2024 - jaad.org
Anifrolumab is a first-in-class type I interferon receptor antibody approved by the United
States Food and Drug Administration in 2021 for moderate to severe systemic lupus …
States Food and Drug Administration in 2021 for moderate to severe systemic lupus …